Ventricular Assist Device Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

The ventricular assist device market was valued at USD 2.03 Billion in 2025. It is poised to grow at a CAGR of 11.60% during the forecast period of 2026-2035, and reach USD 6.08 Billion by 2035. The market growth is driven by the rising prevalence of advanced heart failure, increasing adoption of left ventricular assist devices, technological advancements, improving survival outcomes, and expanding indications for long-term circulatory support therapies.

Latest News on the Ventricular Assist Device Market (2026)

• In April 2026, BrioHealth Solutions received FDA conditional approval for its pediatric BrioVAD clinical trial, expanding treatment options for advanced heart failure in children.
• In April 2026, the Brio4Kids trial was approved to evaluate a compact ventricular assist system addressing unmet pediatric care needs and improving device adaptability.
• In March 2026, BrioHealth achieved 100 BrioVAD implants across U.S. clinical sites, reflecting increasing physician confidence and growing adoption of next-generation assist technologies.

Key Market Trends and Insights

• By product, the left ventricular assist device segment is likely to dominate, accounting for nearly 80% market share in the historical period.
• By application, the destination therapy segment is likely to lead, holding about 43% market share in the historical period.
• By region, North America is likely to dominate, accounting for above 54% market share in the historical period.

Market Size and Forecast

• Market Size (2025): USD 2.03 Billion
• Projected Market Size (2035): USD 6.08 Billion
• CAGR (2026-2035): 11.60%

Ventricular Assist Device Market Overview

The market is experiencing steady growth driven by the rising prevalence of end-stage heart failure and increasing demand for advanced cardiac support systems. Technological advancements in implantable and wearable devices are improving patient survival and quality of life. The expanding geriatric population, growing transplant shortages, and enhanced healthcare infrastructure further support the adoption of ventricular assist devices globally. The market reached a value of approximately USD 2.03 Billion in 2025.

Ventricular Assist Device Market Growth Drivers

FDA-Approved Pivotal Trial Expected to Accelerate the Market Expansion

The rising prevalence of advanced heart failure and increasing demand for minimally invasive cardiac procedures are key growth drivers. For instance, in April 2026, Supira Medical received FDA approval to initiate the SUPPORT II pivotal trial for its percutaneous ventricular assist device, supporting future U.S. commercialization. This development is expected to accelerate innovation and adoption of mechanical circulatory support systems in the forecast period.

Ventricular Assist Device Market Trends

Key trends shaping the market include technological advancements, rising heart failure prevalence, increasing left ventricular assist devices adoption, and expanding long-term therapy applications globally.

Strategic Acquisition Poised to Enhance Cardiovascular Technology and Market Innovation

The increasing investments in cardiovascular technologies and growing focus on advanced interventional solutions are shaping market trends. For instance, in April 2026, Johnson & Johnson entered an agreement to acquire Atraverse Medical to expand its cardiac ablation portfolio with innovative access technologies. This move is expected to enhance product innovation and strengthen cardiac device innovation trends in the forecast period.

Ventricular Assist Device Market Segmentation

Market Breakup by Type

• Left Ventricular Assist Device (LVAD)
• Right Ventricular Assist Device (RVAD)
• Biventricular Assist Device (BIVAD)

Market Breakup by Application

• Bridge-to-transplant (BTT) Therapy
• Destination Therapy
• Other Therapies

Market Breakup by End User

• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Ventricular Assist Device Market Share

Left Ventricular Assist Device Likely to Dominate the Market Segment by Type

The left ventricular assist device segment is likely to dominate the market, accounting for nearly 80% historical market share. This dominance is driven by rising adoption in advanced heart failure management, improved survival outcomes, and increasing clinical preference for long-term circulatory support solutions, particularly in bridge-to-transplant and destination therapy applications across developed healthcare systems globally.

Ventricular Assist Device Market Analysis by Region

North America is likely to dominate, holding over 54% market share during the historical period. Growth is supported by advanced healthcare infrastructure, high adoption of innovative cardiac technologies, favorable reimbursement frameworks, and increasing prevalence of cardiovascular diseases, alongside the strong presence of leading market players driving continuous product innovation and clinical adoption.

Leading Players in the Ventricular Assist Device Market

The key features of the market report comprise patent analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

The key features of the market report comprise patent analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Abiomed Inc.

Founded in 1981 and headquartered in Danvers, Massachusetts, Abiomed is a leading cardiovascular device company specializing in circulatory support systems. Its portfolio includes the Impella platform, widely used in advanced heart failure and high-risk procedures. The company focuses on innovation in mechanical circulatory support technologies to improve cardiac recovery outcomes.

BiVACOR Inc

Established in 2008 and headquartered in Huntington Beach, California, BiVACOR develops next-generation total artificial heart systems for severe heart failure patients. Its portfolio centers on a titanium-based artificial heart designed for long-term use. In 2025, its device received FDA Breakthrough Device Designation, highlighting advancements in artificial heart technology.

Abbott Laboratories (St. Jude Medical Inc.)

Founded in 1888 and headquartered in Abbott Park, Illinois, it operates a diversified healthcare portfolio, including cardiovascular devices. Its ventricular assist device presence stems from the HeartMate platform, supporting patients with advanced heart failure. The company continues expanding its left ventricular assist device innovations through clinical research and product development initiatives globally.

Medtronic plc

Founded in 1949, the company is headquartered in Galway, Ireland, with operational headquarters in Minneapolis, United States. The company offers a broad cardiovascular portfolio, including historical involvement in ventricular assist technologies. In 2025, Medtronic announced a strategic acquisition to strengthen its device pipeline, reinforcing its position in cardiac device innovation markets.

Other key players in the market are Terumo Corporation, Fisher & Paykel Healthcare Limited, Evaheart, Inc., Calon Cardio-Technology Ltd., Berlin Heart GmbH, and AdjuCor GmbH.

Key Questions Answered in the Ventricular Assist Device Market Report

• What was the ventricular assist device market value in 2025?
• What is the ventricular assist device market forecast outlook for 2026-2035?
• What major factors aid the demand for ventricular assist device market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major ventricular assist device market trends?
• Which type is expected to dominate the market segment?
• Which application is expected to dominate the market segment?
• Which end user is expected to dominate the market segment?
• Who are the key players in the ventricular assist device market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?